Johan Kördel joined Lundbeckfonden Ventures in 2010 as a senior partner. He is a director of Acacia Pharma, Amplyx Pharmaceuticals, Enterome, Iconic Therapeutics, SARomics and VHSquared. Previously, he was a board member of Syntaxin (sold to Ipsen), Celladon, Ziarco (sold to Novartis), River Vision (sold to Horizon), Bonesupport, EQL Pharma and KaroBio. Before joining Lundbeckfonden Ventures, Johan was a co-founder and CEO of Sound Biotech and co-founder and senior vice president of research and business development of Biovitrum (now SOBI). Prior to these positions, he worked a decade in the pharmaceutical company Pharmacia in discovery and early development. Johan trained as a physical chemist at University of Lund, Scripps Research Institute and Harvard Medical School.